Lindbrook Capital’s Verona Pharma VRNA Stock Holding History

Lindbrook Capital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,000	Closed	-$67K	–	2626
2021 Q4	$67K	Buy	+10,000	New	+$51.1K	0.01%	630

Other funds holding VRNA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Lindbrook Capital's VRNA Position: Q1 2022 in Review

Lindbrook Capital sold out of Verona Pharma (VRNA) in Q1 2022, closing a stake of 10,000 shares — an estimated $67K sold.

Lindbrook Capital first reported a position in VRNA in Q4 2021 and held it in 1 quarter. The position peaked at $67K in Q4 2021. 39 funds tracked by Wall St. Rank hold VRNA as of Q1 2022.

Lindbrook Capital reported no remaining Verona Pharma position as of Q1 2022 after selling out during the quarter.
Lindbrook Capital sold 10,000 Verona Pharma shares in Q1 2022, an estimated $67K.
Lindbrook Capital first reported a position in Verona Pharma in Q4 2021 and held it in 1 quarter.
Lindbrook Capital's Verona Pharma position peaked at $67K in Q4 2021.
39 funds tracked by Wall St. Rank held Verona Pharma as of Q1 2022.

Based on Lindbrook Capital's 13F filing for Q1 2022, filed 21 Apr 2022.